Barresi Valeria, Vitarelli Enrica, Cerasoli Serenella
Department of Human Pathology, University of Messina, Messina, Italy.
Virchows Arch. 2009 May;454(5):563-71. doi: 10.1007/s00428-009-0757-3. Epub 2009 Mar 19.
The immunoexpression of the antiangiogenic factor semaphorin3A (SEMA3A) was evaluated in a series of meningiomas. Then, its correlations with the microvessel density (MVD) of the tumors and with the clinicopathological parameters as well with the survival time or recurrence-free interval were investigated. A positive SEMA3A immunostaining was found in most of meningiomas and a significant association was found between a high expression of this protein and a low MVD of the tumors. Moreover, a low SEMA3A immunoexpression was significantly correlated with a higher recurrence rate of meningiomas. In conclusion, our findings suggest a role for SEMA3A as an antiangiogenic factor in meningiomas with its decrease being associated with the development of recurrences. The supplementation of SEMA3A might be used in novel therapeutic antiangiogenic strategies to prevent the recurrence of highly vascularized meningiomas.
在一系列脑膜瘤中评估了抗血管生成因子信号素3A(SEMA3A)的免疫表达。然后,研究了其与肿瘤微血管密度(MVD)、临床病理参数以及生存时间或无复发生存期的相关性。在大多数脑膜瘤中发现SEMA3A免疫染色呈阳性,并且发现该蛋白的高表达与肿瘤的低MVD之间存在显著关联。此外,SEMA3A免疫表达低与脑膜瘤的较高复发率显著相关。总之,我们的研究结果表明SEMA3A作为脑膜瘤中的一种抗血管生成因子发挥作用,其减少与复发的发生有关。补充SEMA3A可能用于新型抗血管生成治疗策略,以预防高血管化脑膜瘤的复发。